A
VKTX icon

AlphaQuest’s Viking Therapeutics VKTX Stock Holding History

AlphaQuest’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,677
Closed -$516K – 2025
2025
Q4 		$516K Buy
14,677
+6,792
+86% +$241K 0.03% 799
2025
Q3 		$207K Sell
7,885
-955
-11% -$28.5K 0.01% 1387
2025
Q2 		$234K Sell
8,840
-2,913
-25% -$76.7K 0.02% 1032
2025
Q1 		$284K Buy
11,753
+9,815
+506% +$310K 0.03% 806
2024
Q4 		$78K Buy
1,938
+858
+79% +$48.9K 0.01% 1173
2024
Q3 		$68.4K Sell
1,080
-178
-14% -$10.4K 0.01% 1357
2024
Q2 		$66.7K Buy
1,258
+696
+124% +$45.6K 0.01% 1026
2024
Q1 		$46.1K Sell
562
-616
-52% -$27.4K 0.01% 943
2023
Q4 		$21.9K Buy
+1,178
New +$15.4K ﹤0.01% 958

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

AlphaQuest's VKTX Position: Q1 2026 in Review

AlphaQuest sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 14,677 shares — an estimated $516K sold.

AlphaQuest first reported a position in VKTX in Q4 2023 and held it in 9 quarters. The position peaked at $516K in Q4 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • AlphaQuest reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 14,677 Viking Therapeutics shares in Q1 2026, an estimated $516K.
  • AlphaQuest first reported a position in Viking Therapeutics in Q4 2023 and held it in 9 quarters.
  • AlphaQuest's Viking Therapeutics position peaked at $516K in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.